ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Quality of life and systemic lupus erythematosus (SLE)"

  • Abstract Number: 782 • 2018 ACR/ARHP Annual Meeting

    Cognitive Impairment and Health-Related Quality of Life in a Lupus Cohort

    Chrisanna Dobrowolski1, Lisa Engel2, Robin Green3, Lesley Ruttan4, Sabrina Lombardi4, Carmela Tartaglia5, Nicole Anderson2, Kenneth Colosimo2, Michelle Vitti2, Dennisse Bonilla2, Joan E. Wither6, Marvin J. Fritzler7, Dorcas Beaton8 and Zahi Touma2, 1University of Ottawa, Ottawa, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Brain and Therapeutics, Toronto Rehabilitation Institute, Toronto, ON, Canada, 4Toronto Rehabilitation Institute, Toronto, ON, Canada, 5University of Toronto, Krembil Neurosciences Centre, Toronto, ON, Canada, 6Genetics and Development, Krembil Research Institute, University Health Network, Toronto, ON, Canada, 7Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 8Mobility Program Clinical Research Unit, St Michael's Hospital, Toronto, ON, Canada

    Background/Purpose: Patients with systemic lupus erythematosus (SLE) are commonly affected by cognitive impairment (CI), with a meta-analysis finding a prevalence of 38%. Despite this high…
  • Abstract Number: 1676 • 2018 ACR/ARHP Annual Meeting

    Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage

    Muhammad Mehmood Riaz1,2, Liang SHEN3, Lay Kheng Teoh4, Rangi Kandane-Rathnayake5 and Aisha Lateef6, 1Department of Medicine, National University Hospital, Singapore, Singapore, 2Department of Medicine, Aga Khan University, karachi, Pakistan, 3Biostatistics Unit, National University Health System, Singapore, Singapore, 4National University Hospital, Division of Rheumatology, University Medicine Cluster, Singapore, Singapore, 5School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, 6Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

     Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease affecting the physical, social, and psychological well-being of patients. Health related quality of life (HRQoL) measures…
  • Abstract Number: 845 • 2017 ACR/ARHP Annual Meeting

    Effectiveness of Brief Group Psychoanalytic Psychotherapy in Patients with Systemic Lupus Erythematosus and Follow-up

    Emilia Sato1,2, Céu Conceiçao3, Ivone Meinão4 and Sergio Blay5, 1Rheumatology Division. Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Div/Dept of Med, Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil, 3Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil, 4Medicine, Universidade Federal de São Paulo, Sao Paulo, Brazil, 5Psychiatry, Escola Paulista de Medicina, Universidade Federal de São Paulo, Sao Paulo, Brazil

    Background/Purpose: There are few studies evaluating the effectiveness of psychotherapy in Systemic Lupus Erythematosus (SLE) patients. Objectives: To evaluate the effectiveness of brief group psychoanalytic…
  • Abstract Number: 1263 • 2017 ACR/ARHP Annual Meeting

    Relevance and Utility of Patient Reported Outcomes Measurement Information System (PROMIS®) Instruments in SLE: A Qualitative Study

    Shanthini Kasturi1, Madeline Epsten2, Adena Batterman3, Roberta Horton3, Juliette Kleinman3, Jillian Rose3, Jackie Szymonifka2, Laura Robbins4 and Lisa A. Mandl1, 1Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Social Work Programs, Hospital for Special Surgery, New York, NY, 4Education & Academic Affairs, Hospital for Special Surgery, New York, NY

    Background/Purpose: The measurement of patient reported outcomes is a priority for patient-centered high value care. This is particularly true in chronic systemic diseases such as…
  • Abstract Number: 1652 • 2017 ACR/ARHP Annual Meeting

    Trajectories of Quality of Life in an Iception Cohort of Lupus Patients and Their Determinants

    William Fung1, Lily Lim2, Jiandong Su3 and Zahi Touma4, 1Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Hospital for Sick Children, Toronto, ON, Canada, 3University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 4Rheumatology, University of Toronto, Division of Rheumatology, Institute of Health Policy, Management and Evaluation, Toronto, ON, Canada

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic disease with varying disease activity levels and morbidities over time; this can affect patients’ health related quality…
  • Abstract Number: 2615 • 2017 ACR/ARHP Annual Meeting

    Non-Pharmacological Treatment on Fatigue, Depression, Disease Activity, and Quality of Life of Systemic Lupus Erythematosus: A Systematic Review

    Monthida Fangtham1, Jacob Louis Nash2, Stephanie Hyon3, Raveendhara R. Bannuru4 and Chenchen Wang3, 1Internal Medicine, University of New Mexico, Albuquerque, NM, 2Health Sciences Library and Informatics Center, University of New Mexico, Albuquerque, NM, 3Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, 4Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA

    Background/Purpose: In recent years, non-pharmacological therapies have been deemed as potentially beneficial for patients with systemic lupus erythematosus (SLE). These include complementary and integrative approaches,…
  • Abstract Number: 2953 • 2017 ACR/ARHP Annual Meeting

    Drivers of Satisfaction with Care in Lupus 

    Bhavika Sethi1, Ailda Nika2, Winston Sequeira3, Joel A. Block4, Sergio Toloza5, Ana Bertoli6, Ivana Blazevic7, Luis M. Vilá8, Ioana Moldovan9, Karina Torralba10, Davide Mazzoni11, Elvira Cicognani11, Sarfaraz Hasni12, Berna Goker13, Seminur Haznedaroglu13, Josiane Bourré-Tessier14, Sandra V. Navarra15, Chi Chiu Mok16, Ann Clarke17, Michael Weisman18, Daniel J. Wallace19 and Meenakshi Jolly3, 1University of Birmingham, Birmingham, United Kingdom, 2Rheumatology, Rush University Medical Center, Chicago, IL, 3Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, 4Division of Rheumatology, Rush University Medical Center, Chicago, IL, 5Rheumatology, Hospital San Juan Batista, Catamarca, Argentina, Catamarca, Argentina, 6Instituto Reumatológico Strusberg, Córdoba, Argentina, 7Rheumatology, Universidad de Buenos Aires, Buenos Aires, Argentina, 8Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, 9Rheumatology, Beaver Medical Group, Redlands, CA, 10Division of Rheumatology, Department of Internal Medicine, Loma Linda University, Loma Linda, CA, 11Department of Psychology, University of Bologna, Bologna, Italy, 12National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 13Internal Medicine-Rheumatology, Gazi University Medical School, Ankara, Turkey, 14Rheumatology, University of Montreal, Montreal, QC, Canada, 15Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, 16Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, 17Division of Rheumatology, University of Calgary, Calgary, AB, Canada, 18Cedars-Sinai Medical Center Division of Rheumatology, Los Angeles, CA, 19Rheumatology, Cedars-Sinai Medical Center, Beverly Hills, CA

    Background/Purpose: Although survival in SLE has improved, quality of life (QOL) remains poor. Physicians aim to reduce suffering and improve health outcomes, while maximizing efficiency…
  • Abstract Number: 1757 • 2016 ACR/ARHP Annual Meeting

    Association of the Lupus Low Disease Activity State (LLDAS) with Health-Related Quality of Life

    Vera Golder1, Rangi Kandane-Rathnayake2, Alberta Y. Hoi3, Molla Huq4, Worawit Louthrenoo5, Yuan An6, Zhanguo Li6, Shue Fen Luo7, Sargunan Sockalingam8, Chak Sing Lau9, Mo Yin Mok10, Aisha Lateef11, Kate Franklyn3, Susan Morton12, Sandra V. Navarra13, Leonid Zamora13, Yeong-Jian Wu7, Laniyati Hamijoyo14, Madelynn Chan15, Sean O'Neill16, Fiona Goldblatt17, Mandana Nikpour18, Eric F Morand3 and Asia Pacific Lupus Collaboration, 1Southern Clinical School, Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 2Rheumatology, Monash University, Melbourne, Australia, 3Centre for Inflammatory Diseases, Monash University, Melbourne, Australia, 4Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, 5Division of Rheumatology, Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand, 6Peking University People's Hospital, Beijing, China, 7Chang Gung University, Taoyuan County, Taiwan, 8University of Malaya, Kuala Lumpur, Malaysia, 9Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, 10Queen Mary Hospital, Hong Kong, Hong Kong, 11Medicine/Rheumatology, National University Health System, Singapore, Singapore, 12Monash Health, Melbourne, Australia, 13Rheumatology, University of Santo Tomas Hospital, Manila, Philippines, 14University of Padjadjaran, Bandung, Indonesia, 15Tan Tock Seng Hospital, Singapore, Singapore, 16University of New South Wales, Sydney, Australia, 17Royal Adelaide Hospital, Adelaide, Australia, 18Melbourne University, Melbourne, Australia

    Background/Purpose:  Systemic lupus erythematosus (SLE) is associated with significant impairment of health-related quality of life (HR-QoL). Recently, meeting a definition of a Lupus Low Disease…
  • Abstract Number: 1763 • 2016 ACR/ARHP Annual Meeting

    Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus Following 7 Years of Treatment Exposure: Impact of Clinical Characteristics over Time

    Vibeke Strand1, Pam Berry2, Xiwu Lin2, Yumi Asukai3, James Fettiplace3 and Sulabha Ramachandran2, 1Stanford University School of Medicine, Palo Alto, CA, 2GSK, Philadelphia, PA, 3GSK, Uxbridge, Middlesex, United Kingdom

    Background/Purpose: Despite improvements in medical care leading to improved survival, systemic lupus erythematosus (SLE) adversely affects patients’ health related quality of life (HRQoL). To explore…
  • Abstract Number: 1770 • 2016 ACR/ARHP Annual Meeting

    The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the First 10 Years

    Murray Urowitz1, Dafna D Gladman2, Nicole Anderson3, Jiandong Su4 and The Systemic Lupus International Collaborating Clinics (SLICC) Group , 1Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada

    The Impact of Comorbidities on Quality of Life in Systemic Lupus Erythematosus in the first 10 years   Background/Purpose: The Medical Outcome Survey Short Form…
  • Abstract Number: 3235 • 2016 ACR/ARHP Annual Meeting

    Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients with Systemic Lupus Erythematosus: Up to 7 Years of Treatment Exposure

    Vibeke Strand1, Pam Berry2, Sulabha Ramachandran2 and James Fettiplace3, 1Stanford University School of Medicine, Palo Alto, CA, 2GSK, Philadelphia, PA, 3GSK, Uxbridge, Middlesex, United Kingdom

    Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that causes long-term organ damage over time and impairment in health-related quality of life (HRQoL).…
  • Abstract Number: 3236 • 2016 ACR/ARHP Annual Meeting

    Socio-Demographic and Clinical Factors Influencing Generic and Disease-Specific Quality of Life in Patients with Systemic Lupus Erythematosus: Results of a Prospective Multicenter Study

    Hervé Devilliers1, Jean-François Besancenot1, Sylvain Audia2, Bernard Bonnotte3, Francois Maurier4, Christiane Broussolle5, Nadine Magy-Bertrand6, Denis Wahl7, Jean-Loup Pennaforte8, Thierry Martin9, Olivier Aumaître10, Gilles Blaison11, Geraldine Muller1, Alexis Mathian12, Christine Binquet13 and Zahir Amoura14, 1Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 2Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon; INSERM, UMR1098, University of Bourgogne Franche-Comté, FHU INCREASE, Dijon, France, 3Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 4Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, 5Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 6CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, 7CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, 8Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, 9Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, 10CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, 11Internal medicine departement, Colmar Hospital, Colmar, France, 12Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 13INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 14Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France

    Background/Purpose: To describe demographic, socio-economic and lupus-related factors associated with health-related quality of life (HRQOL) in systemic lupus erythematosus (SLE), as measured by 2 generic…
  • Abstract Number: 3237 • 2016 ACR/ARHP Annual Meeting

    Responsiveness and Its Magnitude in the 36-Item Short Form Health Survey and the Lupus Quality of Life Questionnaire in Patients with Active Disease

    Stephanie Nantes1, Jiandong Su2 and Zahi Touma3, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: SF-36 and LupusQoL are Health-Related Quality-of-Life (HRQoL) questionnaires used in SLE. We determined: (1) concurrent construct validity of SF-36 and LupusQoL against disease activity…
  • Abstract Number: 1397 • 2016 ACR/ARHP Annual Meeting

    Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE)

    Ashwaq Aleed, CCHMC, cincinnati, OH; Pediatric, Qassim University, Qassim, Saudi Arabia

    Correlation and Responsiveness of Cutaneous Lupus Disease Area and Severity Index (CLASI) and Skindex-29 with Cutaneous Childhood Lupus Erythematosus (cSLE) *Ashwaq AlEÕed, **Nora Al Mutairi ,…
  • Abstract Number: 1419 • 2016 ACR/ARHP Annual Meeting

    Validation of the French Version of Lupus Patient Reported Outcome (LupusPRO), a Disease-Specific Patient Reported Outcome for Lupus Patients

    Hervé Devilliers1, Meenakshi Jolly2, Maxime Samson3, Bernard Bonnotte4, Francois Maurier5, Pascal Sève6, Nadine Magy-Bertrand7, Denis Wahl8, Jean-Loup Pennaforte9, Thierry Martin10, Olivier Aumaître11, Gilles Blaison12, Philip Bielefeld13, Alexis Mathian14, Christine Binquet15 and Zahir Amoura14, 1Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 2Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL, 3Dijon University Hospital, Dijon, France, 4Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, 5Department of Internal Medicine, HP Metz Belle Isle Hospital, Metz, France, 6Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, 7CHU Jean-Minjoz, Service de médecine interne et immunologie clinique, Besançon, France, 8CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France, 9Internal Medicine, Internal medicine departement, CHU de Reims, Reims, France, 10Internal medicine and clinical immunology departement, Strasbourg University Hospital, Strasbourg, France, 11Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 12Internal medicine departement, Colmar Hospital, Colmar, France, 13Internal medicine and systemic disease unit, Dijon University Hospital, Dijon, France, 14Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, 15INSERM, CIC 1432, Clinical Epidemiology Unit, Hôpital François Mitterrand, CHU de Dijon, Dijon, France

    Background/Purpose: To assess validity and reliability of French LupusPRO in France. Methods: After cross-cultural adaptation and harmonization for France, the LupusPRO was administered along with…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology